CVS Health Co. (NYSE:CVS) Stock Position Increased by Hall Laurie J Trustee

Hall Laurie J Trustee grew its stake in shares of CVS Health Co. (NYSE:CVSFree Report) by 0.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,048 shares of the pharmacy operator’s stock after buying an additional 135 shares during the quarter. CVS Health comprises 1.8% of Hall Laurie J Trustee’s holdings, making the stock its 17th biggest position. Hall Laurie J Trustee’s holdings in CVS Health were worth $4,742,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CVS. Cantor Fitzgerald Investment Advisor L.P raised its position in shares of CVS Health by 92.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 377,875 shares of the pharmacy operator’s stock worth $38,245,000 after buying an additional 181,966 shares in the last quarter. United Bank raised its holdings in shares of CVS Health by 7.2% in the 1st quarter. United Bank now owns 18,658 shares of the pharmacy operator’s stock worth $1,888,000 after purchasing an additional 1,260 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of CVS Health by 4,063.8% in the first quarter. Loomis Sayles & Co. L P now owns 12,075 shares of the pharmacy operator’s stock worth $1,222,000 after acquiring an additional 11,785 shares in the last quarter. Zions Bancorporation N.A. increased its position in shares of CVS Health by 116.9% in the first quarter. Zions Bancorporation N.A. now owns 2,572 shares of the pharmacy operator’s stock worth $260,000 after acquiring an additional 1,386 shares in the last quarter. Finally, Ergoteles LLC purchased a new position in shares of CVS Health in the first quarter worth approximately $1,551,000. 75.99% of the stock is currently owned by institutional investors.

CVS Health Stock Up 1.2 %

CVS opened at $78.98 on Thursday. CVS Health Co. has a twelve month low of $64.41 and a twelve month high of $83.25. The firm’s 50-day simple moving average is $75.50 and its 200-day simple moving average is $72.96. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.86. The firm has a market cap of $99.39 billion, a price-to-earnings ratio of 12.23, a PEG ratio of 1.03 and a beta of 0.51.

CVS Health (NYSE:CVSGet Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The firm had revenue of $93.81 billion for the quarter, compared to analyst estimates of $90.58 billion. During the same quarter in the prior year, the firm earned $1.99 EPS. The company’s revenue was up 11.9% on a year-over-year basis. Equities research analysts anticipate that CVS Health Co. will post 8.33 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the sale, the executive vice president now owns 39,765 shares in the company, valued at approximately $3,059,916.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. StockNews.com downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. Royal Bank of Canada lowered their price objective on shares of CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a research report on Thursday, February 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $87.00 price objective on shares of CVS Health in a research report on Thursday, February 8th. Piper Sandler boosted their target price on shares of CVS Health from $93.00 to $94.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Finally, Barclays started coverage on shares of CVS Health in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 target price for the company. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.21.

View Our Latest Analysis on CVS

CVS Health Profile

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Featured Articles

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSFree Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.